SVB Wealth LLC Decreases Stock Position in Thermo Fisher Scientific Inc. $TMO

SVB Wealth LLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,965 shares of the medical research company’s stock after selling 3,331 shares during the quarter. SVB Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,718,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Swiss Life Asset Management Ltd raised its position in shares of Thermo Fisher Scientific by 3.8% during the 4th quarter. Swiss Life Asset Management Ltd now owns 46,801 shares of the medical research company’s stock valued at $27,119,000 after buying an additional 1,721 shares in the last quarter. Sentry Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 4.3% during the 4th quarter. Sentry Investment Management LLC now owns 987 shares of the medical research company’s stock valued at $572,000 after buying an additional 41 shares in the last quarter. Byrne Financial Freedom LLC raised its position in shares of Thermo Fisher Scientific by 7.9% during the 4th quarter. Byrne Financial Freedom LLC now owns 1,505 shares of the medical research company’s stock valued at $872,000 after buying an additional 110 shares in the last quarter. Drive Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $251,000. Finally, Pure Financial Advisors LLC raised its position in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. Pure Financial Advisors LLC now owns 1,407 shares of the medical research company’s stock valued at $815,000 after buying an additional 82 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $452.14 on Tuesday. The company has a market capitalization of $168.02 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The firm’s 50-day moving average is $491.19 and its 200 day moving average is $545.39. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Citigroup upped their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. TD Cowen decreased their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Morgan Stanley restated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $619.65.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.